(Q51834578)

English

PARP inhibitors in BRCA1-/BRCA2-associated and triple-negative breast cancers.

scientific article published in April 2010

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

13 April 2018

http://europepmc.org/abstract/MED/20373860

0 references

PARP inhibitors in BRCA1-/BRCA2-associated and triple-negative breast cancers. (English)

1 reference

Europe PubMed Central

PubMed publication ID

13 April 2018

http://europepmc.org/abstract/MED/20373860

author name string

Justin Stebbing

1

1 reference

Europe PubMed Central

PubMed publication ID

13 April 2018

http://europepmc.org/abstract/MED/20373860

Paul Ellis

2

1 reference

Europe PubMed Central

PubMed publication ID

13 April 2018

http://europepmc.org/abstract/MED/20373860

Andrew Tutt

3

1 reference

Europe PubMed Central

PubMed publication ID

13 April 2018

http://europepmc.org/abstract/MED/20373860

language of work or name

0 references

publication date

1 April 2010

1 reference

Europe PubMed Central

PubMed publication ID

13 April 2018

http://europepmc.org/abstract/MED/20373860

Future Oncology

1 reference

Europe PubMed Central

PubMed publication ID

13 April 2018

http://europepmc.org/abstract/MED/20373860

6

1 reference

Europe PubMed Central

PubMed publication ID

13 April 2018

http://europepmc.org/abstract/MED/20373860

4

1 reference

Europe PubMed Central

PubMed publication ID

13 April 2018

http://europepmc.org/abstract/MED/20373860

485-486

1 reference

Europe PubMed Central

PubMed publication ID

13 April 2018

http://europepmc.org/abstract/MED/20373860

Instability and decay of the primary structure of DNA

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.27

21 January 2018

The roles of BRCA1 and BRCA2 and associated proteins in the maintenance of genomic stability

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.27

21 January 2018

Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.27

21 January 2018

Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.27

21 January 2018

Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.27

21 January 2018

Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.27

21 January 2018

Secondary BRCA1 mutations in BRCA1-mutated ovarian carcinomas with platinum resistance

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.27

21 January 2018

Resistance to therapy caused by intragenic deletion in BRCA2

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.27

21 January 2018

Drug resistance caused by reversion mutation

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.27

21 January 2018

A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.27

21 January 2018

Identifiers

10.2217/FON.10.27

1 reference

Europe PubMed Central

PubMed publication ID

13 April 2018

http://europepmc.org/abstract/MED/20373860

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

13 April 2018

http://europepmc.org/abstract/MED/20373860

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q51834578&oldid=1210076377"